Arkadios Wealth Advisors Invests $255,000 in Elanco Animal Health Incorporated (NYSE:ELAN)

Arkadios Wealth Advisors bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 24,278 shares of the company's stock, valued at approximately $255,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Allworth Financial LP lifted its holdings in Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after buying an additional 2,090 shares during the period. CoreCap Advisors LLC bought a new position in shares of Elanco Animal Health in the 4th quarter worth approximately $29,000. NBC Securities Inc. purchased a new position in shares of Elanco Animal Health in the 1st quarter valued at approximately $40,000. Parallel Advisors LLC boosted its position in shares of Elanco Animal Health by 92.2% during the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after purchasing an additional 1,852 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in shares of Elanco Animal Health by 65.9% during the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after purchasing an additional 1,740 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on ELAN shares. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Leerink Partners raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a research report on Thursday, July 17th. UBS Group upped their price objective on shares of Elanco Animal Health from $17.00 to $18.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Finally, Stifel Nicolaus boosted their price target on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $16.17.

Elanco Animal Health Stock Performance

NYSE ELAN traded up $2.44 during trading hours on Thursday, hitting $16.39. The company's stock had a trading volume of 13,790,253 shares, compared to its average volume of 4,990,467. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $16.70. The company's 50 day simple moving average is $14.26 and its two-hundred day simple moving average is $12.05. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46. The company has a market cap of $8.14 billion, a P/E ratio of 22.14, a price-to-earnings-growth ratio of 2.71 and a beta of 1.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter last year, the firm posted $0.30 EPS. The business's quarterly revenue was up 4.8% compared to the same quarter last year. As a group, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.